Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 755 full-time employees. The company went IPO on 2013-10-30. The firm enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The firm offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). The company has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
Mr. Marc Stapley est le Chief Executive Officer de Veracyte Inc, il a rejoint l'entreprise depuis 2021.
Quelle est la performance du prix de l'action VCYT ?
Le prix actuel de VCYT est de $41.05, il a augmenté de 0.71% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Veracyte Inc ?
Veracyte Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Veracyte Inc ?
La capitalisation boursière actuelle de Veracyte Inc est de $3.2B
Est-ce que Veracyte Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 13 analystes ont établi des notations d'analystes pour Veracyte Inc, y compris 7 achat fort, 7 achat, 2 maintien, 1 vente et 7 vente forte
